ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 160 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $467,911 | -45.8% | 21,865 | +2.3% | 0.01% | -47.1% |
| Q1 2023 | $863,961 | -11.0% | 21,364 | +2.4% | 0.02% | -10.5% |
| Q4 2022 | $970,547 | +8.9% | 20,863 | +21.6% | 0.02% | +5.6% |
| Q3 2022 | $891,000 | +19.9% | 17,157 | +9.2% | 0.02% | +28.6% |
| Q2 2022 | $743,000 | -32.3% | 15,706 | +1.9% | 0.01% | -12.5% |
| Q1 2022 | $1,098,000 | -4.2% | 15,406 | +0.7% | 0.02% | +6.7% |
| Q4 2021 | $1,146,000 | -33.8% | 15,306 | -49.7% | 0.02% | -34.8% |
| Q3 2021 | $1,731,000 | +102.5% | 30,458 | +56.9% | 0.02% | +130.0% |
| Q2 2021 | $855,000 | -10.8% | 19,408 | 0.0% | 0.01% | -9.1% |
| Q1 2021 | $958,000 | +26.2% | 19,408 | +7.8% | 0.01% | +22.2% |
| Q4 2020 | $759,000 | -59.5% | 18,009 | -56.0% | 0.01% | -59.1% |
| Q3 2020 | $1,873,000 | +283.8% | 40,908 | +321.6% | 0.02% | +266.7% |
| Q2 2020 | $488,000 | – | 9,702 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |